{
    "eightKs": [
        {
            "content": "Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review. On November 12, 2020, the Audit Committee of the Board of Directors and executive management determined, after review and discussion with our independent public accounting firm, Marcum LLP, that the Company\u2019s unaudited condensed consolidated interim financial statements for the quarter ended June 30, 2020 should no longer be relied upon. The financial statements for the quarter ended June 30, 2020 as filed with the U.S. Securities and Exchange Commission on August 14, 2020, contained material errors. The Audit Committee concluded that material adjustments to the financial statements for the quarter ended June 30, 2020 are required and that the Company will need to restate them. Specifically, during the course of preparation of the financial statements for the quarter ended September 30, 2020, our Chief Executive Officer and our Chief Financial Officer discovered that revenues",
            "date": "2020-11-17",
            "details": "",
            "filingType": "8-K",
            "link": "https://www.sec.gov//Archives/edgar/data/1367083/000168316820003995/sonoma_8k.htm",
            "nonComplianceType": "",
            "nonCompliant": false,
            "tags": []
        },
        {
            "content": " Entry into a Material Definitive Agreement. On March 26, 2021, we entered into a licensing and distribution agreement with EMC Pharma, LLC, for the exclusive right to sell and distribute prescription dermatological and eye care products based on our Microcyn\u00ae technology in the United States. EMC has to purchase certain minimum product quantities and pay a quarterly royalty to retain the exclusive rights. The agreement has a five-year initial term, subject to mutual extension. This report contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements related to our future activities or future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performances and involve risks, uncert",
            "date": "2021-03-31",
            "details": "",
            "filingType": "8-K",
            "link": "https://www.sec.gov//Archives/edgar/data/1367083/000168316821001155/sonoma_8k.htm",
            "nonComplianceType": "",
            "nonCompliant": false,
            "tags": []
        },
        {
            "content": " Regulation FD Disclosure. Attached is the updated investor presentation for certain investor conferences in March 2021. The presentation materials are furnished hereto as Exhibit 99.1. This report contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements related to our future activities or future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performances and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including those risks discussed in our annual report on Form 10-K and in other docume",
            "date": "2021-03-04",
            "details": "",
            "filingType": "8-K",
            "link": "https://www.sec.gov//Archives/edgar/data/1367083/000168316821000780/sonoma_8k.htm",
            "nonComplianceType": "",
            "nonCompliant": false,
            "tags": []
        },
        {
            "content": " Regulation FD Disclosure. Attached is the investor presentation for the H.C. Wainwright Bioconnect 2021 Virtual Conference. The presentation materials are furnished hereto as Exhibit 99.1. This report contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements related to our future activities or future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performances and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including those risks discussed in our annual report on Form 10-K and in other do",
            "date": "2021-01-11",
            "details": "",
            "filingType": "8-K",
            "link": "https://www.sec.gov//Archives/edgar/data/1367083/000168316821000091/sonoma_8k2.htm",
            "nonComplianceType": "",
            "nonCompliant": false,
            "tags": []
        },
        {
            "content": " Entry into a Material Definitive Agreement. On December 4, 2020, we entered into an exclusive licensing and distribution agreement with Crown Laboratories, Inc., for the right to sell over-the-counter dermatological private-label products treating itch based on our Microcyn\u00ae technology in the United States. Crown Laboratories has to purchase certain minimum product quantities to retain the exclusive rights. The agreement has a two-year initial term and a five-year term thereafter, subject to mutual extension. This report contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements related to our future activities or future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future perf",
            "date": "2020-12-10",
            "details": "",
            "filingType": "8-K",
            "link": "https://www.sec.gov//Archives/edgar/data/1367083/000168316820004251/sonoma_8k.htm",
            "nonComplianceType": "",
            "nonCompliant": false,
            "tags": []
        },
        {
            "content": "Departure of Directors of Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Option Grants On January 7, 2021, we awarded stock options to certain executive officers of the Company. The grant was part of the annual company-wide grant to all employees in recognition of their services. The exercise price of the options is based on the closing price of our common stock of $8.03 per share on January 7, 2021, and the options vest in three equal tranches on the first, second and third anniversary of the grant date. All options vest upon change of control. Any unvested options will expire if the employment of the respective executive terminates prior to the vesting date. The option grants are as follows: \u00b7 Amy Trombly, Chief Executive Officer: 27,777 options;  \u00b7 Jerry Dvonch, Chief Financial Officer: 27,777 options; and  \u00b7 Bruce Thornton, Chief Operations Officer: 27,777 options. Addendum to Employment Agreement with our",
            "date": "2021-01-08",
            "details": "",
            "filingType": "8-K",
            "link": "https://www.sec.gov//Archives/edgar/data/1367083/000168316821000064/sonoma_8k.htm",
            "nonComplianceType": "",
            "nonCompliant": false,
            "tags": []
        },
        {
            "content": " Entry into a Material Definitive Agreement. On December 14, 2020, we entered into a non-exclusive licensing and distribution agreement with Gabriel Science, LLC, for the right to sell hypochlorous acid products into the dental, head and neck markets in the United States. The agreement has a one-year initial term, subject to mutual extension. This report contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements related to our future activities or future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performances and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed",
            "date": "2020-12-17",
            "details": "",
            "filingType": "8-K",
            "link": "https://www.sec.gov//Archives/edgar/data/1367083/000168316820004342/sonoma_8k.htm",
            "nonComplianceType": "",
            "nonCompliant": false,
            "tags": []
        }
    ],
    "importantItems": [
        {
            "date": "03/31/2021",
            "details": "Sonoma Pharmaceuticals and EMC Pharma Announce an Exclusive Partnership to Expand Commercial Channels of the Microcyn\u00ae-based Rx Dermatology and Eye Care Products Nationwide",
            "kind": "",
            "nonCompliant": false,
            "sourceLink": "https://finance.yahoo.com/news/sonoma-pharmaceuticals-emc-pharma-announce-201000929.html",
            "sourceType": "Press Release",
            "tag": ""
        }
    ],
    "na": false,
    "ownership": {
        "calculatedFloat": 0,
        "date": "",
        "footnotes": null,
        "rows": null,
        "sharesOutstanding": 0,
        "source": "",
        "sourceType": "",
        "sumActual": 0,
        "textbookFloat": 0
    },
    "shelfs": [
        {
            "baseType": "S-3",
            "effective": "2020-12-22 16:30:00",
            "exemptOffering": false,
            "expirationDate": "2023-12-22 16:30:00 +0000 UTC",
            "expired": false,
            "fileID": "333-250925",
            "filings": [
                {
                    "AmountSold": 0,
                    "AtmIncreased": false,
                    "IsLatestPreliminary": false,
                    "IsSupplement": false,
                    "addToRemaining": false,
                    "aggregateAmount": 63425000,
                    "amendmentType": "",
                    "atmRemaining": 0,
                    "date": "2020-12-23",
                    "documentUrl": "https://www.sec.gov/Archives/edgar/data/1367083/000168316820004441/sonoma_424b5.htm",
                    "error": "",
                    "explanatoryNote": "",
                    "fileID": "333-250925",
                    "fileUrl": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&filenum=333-250925&owner=exclude&count=40",
                    "filingType": "424B5",
                    "float": "2056891",
                    "foreign": false,
                    "hasATM": false,
                    "hasResale": false,
                    "hasResaleBase": false,
                    "hasResaleSupplement": false,
                    "hiddenATM": "",
                    "ib6": "0",
                    "isAmendment": false,
                    "isHybrid": false,
                    "isIPO": false,
                    "mvphs": "$17,380,729 ",
                    "offeringInfo": "",
                    "offeringType": "",
                    "placementAgent": "",
                    "prefundedExercise": "",
                    "prefundedWarrants": "",
                    "price": 17380729,
                    "remaining": 0,
                    "resaleAggregate": 0,
                    "resaleShares": "",
                    "sharesOffered": 0,
                    "sharesOutstanding": "",
                    "sharesOutstandingPrior": "",
                    "show": true,
                    "subjectToCompletion": false,
                    "warrants": []
                },
                {
                    "AmountSold": 0,
                    "AtmIncreased": false,
                    "IsLatestPreliminary": false,
                    "IsSupplement": false,
                    "addToRemaining": false,
                    "aggregateAmount": 63425000,
                    "amendmentType": "",
                    "atmRemaining": 0,
                    "date": "2020-12-15",
                    "documentUrl": "https://www.sec.gov/Archives/edgar/data/1367083/000168316820004297/sonoma_s3a1.htm",
                    "error": "",
                    "explanatoryNote": "",
                    "fileID": "333-250925",
                    "fileUrl": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&filenum=333-250925&owner=exclude&count=40",
                    "filingType": "S-3/A",
                    "float": "2026741",
                    "foreign": false,
                    "hasATM": false,
                    "hasResale": false,
                    "hasResaleBase": false,
                    "hasResaleSupplement": false,
                    "hiddenATM": "",
                    "ib6": "0",
                    "isAmendment": false,
                    "isHybrid": false,
                    "isIPO": false,
                    "mvphs": "$17,754,251 ",
                    "offeringInfo": "",
                    "offeringType": "",
                    "placementAgent": "",
                    "prefundedExercise": "",
                    "prefundedWarrants": "",
                    "price": 17754251,
                    "remaining": 63425000,
                    "resaleAggregate": 0,
                    "resaleShares": "",
                    "sharesOffered": 0,
                    "sharesOutstanding": "",
                    "sharesOutstandingPrior": "",
                    "show": true,
                    "subjectToCompletion": false,
                    "warrants": null
                },
                {
                    "AmountSold": 0,
                    "AtmIncreased": false,
                    "IsLatestPreliminary": false,
                    "IsSupplement": false,
                    "addToRemaining": false,
                    "aggregateAmount": 63425000,
                    "amendmentType": "",
                    "atmRemaining": 0,
                    "date": "2020-11-24",
                    "documentUrl": "https://www.sec.gov/Archives/edgar/data/1367083/000168316820004085/sonoma_s3.htm",
                    "error": "",
                    "explanatoryNote": "",
                    "fileID": "333-250925",
                    "fileUrl": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&filenum=333-250925&owner=exclude&count=40",
                    "filingType": "S-3",
                    "float": "2026741",
                    "foreign": false,
                    "hasATM": false,
                    "hasResale": false,
                    "hasResaleBase": false,
                    "hasResaleSupplement": false,
                    "hiddenATM": "",
                    "ib6": "$1,563,020",
                    "isAmendment": false,
                    "isHybrid": false,
                    "isIPO": false,
                    "mvphs": "$13,437,293 ",
                    "offeringInfo": "",
                    "offeringType": "",
                    "placementAgent": "",
                    "prefundedExercise": "",
                    "prefundedWarrants": "",
                    "price": 13437293,
                    "remaining": 63425000,
                    "resaleAggregate": 0,
                    "resaleShares": "",
                    "sharesOffered": 0,
                    "sharesOutstanding": "",
                    "sharesOutstandingPrior": "",
                    "show": true,
                    "subjectToCompletion": false,
                    "warrants": null
                }
            ],
            "foreign": false,
            "hasATM": false,
            "hasHiddenATM": false,
            "isIPO": false,
            "latestFilingDate": "2020-12-23",
            "show": true
        },
        {
            "baseType": "S-1",
            "effective": "2018-11-16 16:30:00",
            "exemptOffering": false,
            "expirationDate": "2021-11-15 16:30:00 +0000 UTC",
            "expired": false,
            "fileID": "333-227806",
            "filings": [
                {
                    "AmountSold": 0,
                    "AtmIncreased": false,
                    "IsLatestPreliminary": false,
                    "IsSupplement": false,
                    "addToRemaining": false,
                    "aggregateAmount": 7300000,
                    "amendmentType": "",
                    "atmRemaining": 0,
                    "date": "2018-11-20",
                    "documentUrl": "https://www.sec.gov/Archives/edgar/data/1367083/000168316818003517/sonoma_424.htm",
                    "error": "",
                    "explanatoryNote": "",
                    "fileID": "333-227806",
                    "fileUrl": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&filenum=333-227806&owner=exclude&count=40",
                    "filingType": "424B5",
                    "float": "",
                    "foreign": false,
                    "hasATM": false,
                    "hasResale": false,
                    "hasResaleBase": false,
                    "hasResaleSupplement": false,
                    "hiddenATM": "",
                    "ib6": "",
                    "isAmendment": false,
                    "isHybrid": false,
                    "isIPO": false,
                    "mvphs": "",
                    "offeringInfo": "",
                    "offeringType": "",
                    "placementAgent": "Dawson James Securities",
                    "prefundedExercise": "",
                    "prefundedWarrants": "",
                    "price": 1,
                    "remaining": 5504990,
                    "resaleAggregate": 0,
                    "resaleShares": "",
                    "sharesOffered": 11497500,
                    "sharesOutstanding": "",
                    "sharesOutstandingPrior": "",
                    "show": true,
                    "subjectToCompletion": false,
                    "warrants": [
                        "42,857@$4.375"
                    ]
                },
                {
                    "AmountSold": 0,
                    "AtmIncreased": false,
                    "IsLatestPreliminary": false,
                    "IsSupplement": false,
                    "addToRemaining": false,
                    "aggregateAmount": 12804990,
                    "amendmentType": "",
                    "atmRemaining": 0,
                    "date": "2018-11-16",
                    "documentUrl": "https://www.sec.gov/Archives/edgar/data/1367083/000168316818003469/sonoma_s1a2.htm",
                    "error": "",
                    "explanatoryNote": "",
                    "fileID": "333-227806",
                    "fileUrl": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&filenum=333-227806&owner=exclude&count=40",
                    "filingType": "S-1/A",
                    "float": "",
                    "foreign": false,
                    "hasATM": false,
                    "hasResale": false,
                    "hasResaleBase": false,
                    "hasResaleSupplement": false,
                    "hiddenATM": "",
                    "ib6": "",
                    "isAmendment": false,
                    "isHybrid": false,
                    "isIPO": false,
                    "mvphs": "",
                    "offeringInfo": "",
                    "offeringType": "",
                    "placementAgent": "Dawson James Securities",
                    "prefundedExercise": "",
                    "prefundedWarrants": "",
                    "price": 0,
                    "remaining": 12804990,
                    "resaleAggregate": 0,
                    "resaleShares": "",
                    "sharesOffered": 11497500,
                    "sharesOutstanding": "",
                    "sharesOutstandingPrior": "",
                    "show": true,
                    "subjectToCompletion": false,
                    "warrants": null
                },
                {
                    "AmountSold": 0,
                    "AtmIncreased": false,
                    "IsLatestPreliminary": false,
                    "IsSupplement": false,
                    "addToRemaining": false,
                    "aggregateAmount": 12804990,
                    "amendmentType": "",
                    "atmRemaining": 0,
                    "date": "2018-11-07",
                    "documentUrl": "https://www.sec.gov/Archives/edgar/data/1367083/000168316818003262/sonoma_s1a1.htm",
                    "error": "",
                    "explanatoryNote": "",
                    "fileID": "333-227806",
                    "fileUrl": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&filenum=333-227806&owner=exclude&count=40",
                    "filingType": "S-1/A",
                    "float": "",
                    "foreign": false,
                    "hasATM": false,
                    "hasResale": false,
                    "hasResaleBase": false,
                    "hasResaleSupplement": false,
                    "hiddenATM": "",
                    "ib6": "",
                    "isAmendment": false,
                    "isHybrid": false,
                    "isIPO": false,
                    "mvphs": "",
                    "offeringInfo": "",
                    "offeringType": "",
                    "placementAgent": "Dawson James Securities",
                    "prefundedExercise": "",
                    "prefundedWarrants": "",
                    "price": 0,
                    "remaining": 12804990,
                    "resaleAggregate": 0,
                    "resaleShares": "",
                    "sharesOffered": 11497500,
                    "sharesOutstanding": "",
                    "sharesOutstandingPrior": "",
                    "show": true,
                    "subjectToCompletion": false,
                    "warrants": null
                },
                {
                    "AmountSold": 0,
                    "AtmIncreased": false,
                    "IsLatestPreliminary": false,
                    "IsSupplement": false,
                    "addToRemaining": false,
                    "aggregateAmount": 6000000,
                    "amendmentType": "",
                    "atmRemaining": 0,
                    "date": "2018-10-12",
                    "documentUrl": "https://www.sec.gov/Archives/edgar/data/1367083/000168316818003037/sonoma_s1.htm",
                    "error": "",
                    "explanatoryNote": "",
                    "fileID": "333-227806",
                    "fileUrl": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&filenum=333-227806&owner=exclude&count=40",
                    "filingType": "S-1",
                    "float": "",
                    "foreign": false,
                    "hasATM": false,
                    "hasResale": false,
                    "hasResaleBase": false,
                    "hasResaleSupplement": false,
                    "hiddenATM": "",
                    "ib6": "",
                    "isAmendment": false,
                    "isHybrid": false,
                    "isIPO": false,
                    "mvphs": "",
                    "offeringInfo": "",
                    "offeringType": "",
                    "placementAgent": "",
                    "prefundedExercise": "",
                    "prefundedWarrants": "",
                    "price": 0,
                    "remaining": 6000000,
                    "resaleAggregate": 0,
                    "resaleShares": "",
                    "sharesOffered": 6479633,
                    "sharesOutstanding": "",
                    "sharesOutstandingPrior": "",
                    "show": true,
                    "subjectToCompletion": false,
                    "warrants": null
                }
            ],
            "foreign": false,
            "hasATM": false,
            "hasHiddenATM": false,
            "isIPO": false,
            "latestFilingDate": "2018-11-20",
            "show": true
        }
    ],
    "stockInfo": {
        "exchange": "NASDAQ",
        "float": "2.05M",
        "income": "-2.60M",
        "io": "8.80%",
        "marketCap": "15.23M",
        "name": "Sonoma Pharmaceuticals, Inc.",
        "news": [
            {
                "anchor": "https://finance.yahoo.com/news/sonoma-pharmaceuticals-emc-pharma-announce-201000929.html",
                "date": "Mar-31-21 ",
                "source": "Business Wire",
                "text": "Sonoma Pharmaceuticals and EMC Pharma Announce an Exclusive Partnership to Expand Commercial Channels of the Microcyn\u00ae-based Rx Dermatology and Eye Care Products Nationwide"
            },
            {
                "anchor": "https://finance.yahoo.com/news/sonoma-pharmaceuticals-alert-bragar-eagel-020000410.html",
                "date": "Mar-11-21 ",
                "source": "Business Wire",
                "text": "SONOMA PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. Is Investigating Sonoma Pharmaceuticals, Inc. on Behalf of Sonoma Stockholders and Encourages Investors to Contact the Firm"
            },
            {
                "anchor": "https://finance.yahoo.com/news/rosen-nationally-regarded-investor-counsel-011500852.html",
                "date": "Mar-09-21 ",
                "source": "Business Wire",
                "text": "ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Sonoma Pharmaceuticals, Inc. Investors with Losses to Inquire About Securities Class Action Investigation  SNOA"
            },
            {
                "anchor": "https://finance.yahoo.com/news/sonoma-pharmaceuticals-present-upcoming-spring-220300211.html",
                "date": "Mar-04-21 ",
                "source": "Business Wire",
                "text": "Sonoma Pharmaceuticals to Present at Upcoming Spring Virtual Investor Conferences"
            },
            {
                "anchor": "https://finance.yahoo.com/news/sonoma-pharmaceuticals-reports-third-quarter-223000844.html",
                "date": "Feb-16-21 ",
                "source": "Business Wire",
                "text": "Sonoma Pharmaceuticals Reports Third Quarter FY 2021 Financial Results"
            },
            {
                "anchor": "https://finance.yahoo.com/news/breaking-alert-rosen-longstanding-trusted-204500811.html",
                "date": "Feb-15-21 ",
                "source": "GlobeNewswire",
                "text": "BREAKING ALERT: ROSEN, A LONGSTANDING AND TRUSTED FIRM, Encourages Sonoma Pharmaceuticals, Inc. Investors with Losses to Inquire About Securities Class Action Investigation  SNOA"
            },
            {
                "anchor": "https://finance.yahoo.com/news/important-investor-alert-schall-law-175000712.html",
                "date": "Feb-10-21 ",
                "source": "ACCESSWIRE",
                "text": "IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sonoma Pharmaceuticals, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm"
            },
            {
                "anchor": "https://finance.yahoo.com/news/sonoma-pharmaceuticals-inc-company-investigated-130000884.html",
                "date": "Feb-02-21 ",
                "source": "GlobeNewswire",
                "text": "Sonoma Pharmaceuticals, Inc.: Company Investigated by the Portnoy Law Firm"
            },
            {
                "anchor": "https://finance.yahoo.com/news/ongoing-investigation-reminder-schall-law-204700275.html",
                "date": "Feb-01-21 ",
                "source": "PR Newswire",
                "text": "ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Sonoma Pharmaceuticals, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm"
            },
            {
                "anchor": "https://finance.yahoo.com/news/sonoma-pharmaceuticals-microderm-technologies-announce-213000017.html",
                "date": "Jan-28-21 ",
                "source": "Business Wire",
                "text": "Sonoma Pharmaceuticals and Microderm Technologies Announce that Dermodacyn\u00ae Disinfecting Solution is Now Available in Hong Kong and Thailand"
            },
            {
                "anchor": "https://finance.yahoo.com/news/ongoing-investigation-alert-schall-law-193000376.html",
                "date": "Jan-27-21 ",
                "source": "ACCESSWIRE",
                "text": "ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sonoma Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm"
            },
            {
                "anchor": "https://finance.yahoo.com/news/rosen-global-investor-counsel-continues-230000242.html",
                "date": "Jan-18-21 ",
                "source": "PR Newswire",
                "text": "ROSEN, GLOBAL INVESTOR COUNSEL, Continues To Investigate Securities Claims Against Sonoma Pharmaceuticals, Inc. - SNOA"
            },
            {
                "anchor": "https://finance.yahoo.com/news/shareholder-action-notice-schall-law-164500571.html",
                "date": "Jan-14-21 ",
                "source": "ACCESSWIRE",
                "text": "SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Sonoma Pharmaceuticals, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm"
            },
            {
                "anchor": "https://finance.yahoo.com/news/sonoma-pharmaceuticals-present-h-c-223000064.html",
                "date": "Jan-11-21 ",
                "source": "Business Wire",
                "text": "Sonoma Pharmaceuticals to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference"
            },
            {
                "anchor": "https://finance.yahoo.com/news/rosen-leading-investor-firm-continues-210700077.html",
                "date": "Dec-24-20 ",
                "source": "Business Wire",
                "text": "ROSEN, A LEADING INVESTOR FIRM, Continues To Investigate Securities Claims Against Sonoma Pharmaceuticals, Inc.  SNOA"
            },
            {
                "anchor": "https://finance.yahoo.com/news/shareholder-alert-pomerantz-law-firm-054000986.html",
                "date": "Dec-23-20 ",
                "source": "ACCESSWIRE",
                "text": "SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims  On Behalf of Investors of Sonoma Pharmaceuticals, Inc. - SNOA"
            },
            {
                "anchor": "https://finance.yahoo.com/news/shareholder-alert-pomerantz-law-firm-043500220.html",
                "date": "Dec-19-20 ",
                "source": "GlobeNewswire",
                "text": "SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sonoma Pharmaceuticals, Inc. - SNOA"
            },
            {
                "anchor": "https://finance.yahoo.com/news/rosen-respected-investor-counsel-continues-231700433.html",
                "date": "Dec-17-20 ",
                "source": "GlobeNewswire",
                "text": "ROSEN, RESPECTED INVESTOR COUNSEL, Continues Its Investigation of Securities Claims Against Sonoma Pharmaceuticals, Inc.  SNOA"
            },
            {
                "anchor": "https://finance.yahoo.com/news/sonoma-pharmaceuticals-announces-partnership-gabriel-211000179.html",
                "date": "Dec-17-20 ",
                "source": "Business Wire",
                "text": "Sonoma Pharmaceuticals Announces Partnership with Gabriel Science, LLC For Dental Markets"
            },
            {
                "anchor": "https://finance.yahoo.com/news/shareholder-alert-pomerantz-law-firm-010800691.html",
                "date": "Dec-12-20 ",
                "source": "GlobeNewswire",
                "text": "SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sonoma Pharmaceuticals, Inc. - SNOA"
            },
            {
                "anchor": "https://finance.yahoo.com/news/sonoma-pharmaceuticals-crown-laboratories-announce-211000712.html",
                "date": "Dec-10-20 ",
                "source": "Business Wire",
                "text": "Sonoma Pharmaceuticals and Crown Laboratories Announce an Exclusive Partnership to Launch Microcyn\u00ae Technology-Based Anti-Itch Over-the-Counter Products"
            },
            {
                "anchor": "https://finance.yahoo.com/news/shareholder-alert-pomerantz-law-firm-043000209.html",
                "date": "Dec-09-20 ",
                "source": "ACCESSWIRE",
                "text": "SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims  On Behalf of Investors of Sonoma Pharmaceuticals, Inc. - SNOA"
            },
            {
                "anchor": "https://finance.yahoo.com/news/shareholder-alert-pomerantz-law-firm-011300924.html",
                "date": "Dec-07-20 ",
                "source": "GlobeNewswire",
                "text": "SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims\u00a0On Behalf of Investors of Sonoma Pharmaceuticals, Inc. - SNOA"
            },
            {
                "anchor": "https://finance.yahoo.com/news/shareholder-alert-pomerantz-law-firm-022000582.html",
                "date": "Dec-05-20 ",
                "source": "ACCESSWIRE",
                "text": "SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims  On Behalf of Investors of Sonoma Pharmaceuticals, Inc. - SNOA"
            }
        ],
        "price": "7.43",
        "profile": "Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for various applications, including wound care, animal health care, eye care, oral care, and dermatological conditions in the United States and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, a hypochlorous acid (HOCl) based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a product indicated to promote healing through the management of new and old scars resulting from surgical procedures and trauma wounds or burns; SebuDerm, a product indicated to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis; and Ceramax, a Lipogrid based skin barrier cream for management of dry itchy skin, minor skin irritations, rashes, and inflammation caused by various skin conditions, as well as Loyon for the management of skin scaling. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a line of products designed to stimulate expedited healing by targeting various pathogens, as well as antibiotic-resistant strains that slow natural healing of wounds. In addition, the company offers MicrocynAH and MicrocynVS, which are HOCl-based solutions designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Pediacyn, Epicyn, Gramaderm, and Microdacyn for dermatoses, scar management, and acne; and Sinudox for nasal irrigation, including moistening of cuts, abrasions, and lacerations located in the nasal cavity. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.",
        "sectorsAndCountry": "Healthcare | Drug Manufacturers - Specialty & Generic | USA",
        "sharesOutstanding": "2.08M",
        "shortOfFloat": "0.05%",
        "sixtyDayVWAP": 9.64,
        "symbol": "SNOA",
        "url": "https://finviz.com/quote.ashx?t=SNOA"
    },
    "tenQ": {
        "filingType": "10-Q",
        "iXBRL": false,
        "stats": {
            "balanceSheetHTML": "",
            "balanceSheetUrl": "https://www.sec.gov/Archives/edgar/data/1367083/000168316821000580/R2.htm",
            "cash": "5.5M",
            "cashBurnMonthly": "211.3k",
            "cashFlowHTML": "",
            "cashFlowUrl": "https://www.sec.gov/Archives/edgar/data/1367083/000168316821000580/R5.htm",
            "cashLeft": "4.9M",
            "cashUsed": "640.3k",
            "currentRatio": 4.18,
            "date": "Dec. 31, 2020",
            "isNegative": true,
            "monthsOfCash": "23.190000",
            "na": false,
            "netCashOperating": "-1.9M",
            "quickRatio": 1.43,
            "sharesOutstanding": "",
            "totalCurrentAssets": "16.2M",
            "totalCurrentLiabilities": "3.8M"
        },
        "tenQDocument": {
            "content": "",
            "conversionPrices": null,
            "lagcT": "Liquidity and Capital Resources",
            "link": "https://www.sec.gov//Archives/edgar/data/1367083/000168316821000580/sonoma_10q-123120.htm",
            "liquidityAndGoingConcern": "We reported a net loss of $650,000 and $290,000 for the three and nine months ended December 31, 2020. We reported a net loss of $1,084,000 and $1,572,000 for the three and nine months ended December 31, 2019. At December 31, 2020 and March 31, 2020, our accumulated deficit amounted to $172,536,000 and $172,246,000, respectively. As of December 31, 2020, we had cash and cash equivalents of $5,541,000 compared to $3,727,000 on December 31, 2019. Since our inception, substantially all of our operations have been financed through sales of equity securities. Other sources of financing that we have used to date include our revenues, as well as various loans and the sale of certain assets to Invekra, Petagon, Microsafe and Infinity Labs.  31  Since October 1, 2019, substantially all of our operations have been financed through the following transactions:"
        }
    },
    "ticker": "SNOA",
    "timelines": {
        "float": [
            {
                "amount": 2026741,
                "date": "2020-11-24",
                "filingType": "S-3",
                "sourceID": "333-250925",
                "sourceLink": "https://www.sec.gov/Archives/edgar/data/1367083/000168316820004085/sonoma_s3.htm",
                "tag": ""
            },
            {
                "amount": 2026741,
                "date": "2020-12-15",
                "filingType": "S-3/A",
                "sourceID": "333-250925",
                "sourceLink": "https://www.sec.gov/Archives/edgar/data/1367083/000168316820004297/sonoma_s3a1.htm",
                "tag": ""
            },
            {
                "amount": 2056891,
                "date": "2020-12-23",
                "filingType": "424B5",
                "sourceID": "333-250925",
                "sourceLink": "https://www.sec.gov/Archives/edgar/data/1367083/000168316820004441/sonoma_424b5.htm",
                "tag": ""
            }
        ],
        "os": [
            {
                "amount": 2077392,
                "date": "Dec. 31, 2020",
                "filingType": "10-Q",
                "sourceID": "",
                "sourceLink": "https://www.sec.gov//Archives/edgar/data/1367083/000168316821000580/sonoma_10q-123120.htm",
                "tag": ""
            }
        ]
    }
}